Literature DB >> 26011469

A Cluster of Proteins Implicated in Kidney Disease Is Increased in High-Density Lipoprotein Isolated from Hemodialysis Subjects.

Baohai Shao1, Ian de Boer1, Chongren Tang1, Philip S Mayer1, Leila Zelnick1, Maryam Afkarian1, Jay W Heinecke1, Jonathan Himmelfarb1.   

Abstract

Cardiovascular disease is the leading cause of death in end-stage renal disease (ESRD) patients treated with hemodialysis. An important contributor might be a decline in the cardioprotective effects of high-density lipoprotein (HDL). One important factor affecting HDL's cardioprotective properties may involve the alterations of protein composition in HDL. In the current study, we used complementary proteomics approaches to detect and quantify relative levels of proteins in HDL isolated from control and ESRD subjects. Shotgun proteomics analysis of HDL isolated from 20 control and 40 ESRD subjects identified 63 proteins in HDL. Targeted quantitative proteomics by isotope-dilution selective reaction monitoring revealed that 22 proteins were significantly enriched and 6 proteins were significantly decreased in ESRD patients. Strikingly, six proteins implicated in renal disease, including B2M, CST3, and PTGDS, were markedly increased in HDL of uremic subjects. Moreover, several of these proteins (SAA1, apoC-III, PON1, etc.) have been associated with atherosclerosis. Our observations indicate that the HDL proteome is extensively remodeled in uremic subjects. Alterations of the protein cargo of HDL might impact HDL's proposed cardioprotective properties. Quantifying proteins in HDL may be useful in the assessment of cardiovascular risk in patients with ESRD and in assessing response to therapeutic interventions.

Entities:  

Keywords:  cardiovascular diseases; end-stage renal disease; hemodialysis; high-density lipoprotein; mass spectrometry; proteomics; selected reaction monitoring; shotgun proteomics

Mesh:

Substances:

Year:  2015        PMID: 26011469      PMCID: PMC4636116          DOI: 10.1021/acs.jproteome.5b00060

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  74 in total

Review 1.  A human proteome detection and quantitation project.

Authors:  N Leigh Anderson; Norman G Anderson; Terry W Pearson; Christoph H Borchers; Amanda G Paulovich; Scott D Patterson; Michael Gillette; Ruedi Aebersold; Steven A Carr
Journal:  Mol Cell Proteomics       Date:  2009-01-07       Impact factor: 5.911

Review 2.  High-density lipoprotein and atherosclerosis: the role of antioxidant activity.

Authors:  Salman Bandeali; John Farmer
Journal:  Curr Atheroscler Rep       Date:  2012-04       Impact factor: 5.113

3.  Comparison of measured GFR, serum creatinine, cystatin C, and beta-trace protein to predict ESRD in African Americans with hypertensive CKD.

Authors:  Nrupen A Bhavsar; Lawrence J Appel; John W Kusek; Gabriel Contreras; George Bakris; Josef Coresh; Brad C Astor
Journal:  Am J Kidney Dis       Date:  2011-09-22       Impact factor: 8.860

Review 4.  High-density lipoprotein--the clinical implications of recent studies.

Authors:  D J Gordon; B M Rifkind
Journal:  N Engl J Med       Date:  1989-11-09       Impact factor: 91.245

5.  Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate.

Authors:  Wolfgang Koenig; Dorothee Twardella; Hermann Brenner; Dietrich Rothenbacher
Journal:  Clin Chem       Date:  2004-11-24       Impact factor: 8.327

Review 6.  Lipotoxicity and impaired high density lipoprotein-mediated reverse cholesterol transport in chronic kidney disease.

Authors:  Nosratola D Vaziri
Journal:  J Ren Nutr       Date:  2010-09       Impact factor: 3.655

7.  Lipids, diabetes, and coronary heart disease: insights from the Framingham Study.

Authors:  W B Kannel
Journal:  Am Heart J       Date:  1985-11       Impact factor: 4.749

8.  Characterization of two post-translationally processed forms of human serum retinol-binding protein: altered ratios in chronic renal failure.

Authors:  S Jaconi; K Rose; G J Hughes; J H Saurat; G Siegenthaler
Journal:  J Lipid Res       Date:  1995-06       Impact factor: 5.922

9.  Provision of antioxidant therapy in hemodialysis (PATH): a randomized clinical trial.

Authors:  Jonathan Himmelfarb; T Alp Ikizler; Charles Ellis; Pingsheng Wu; Ayumi Shintani; Sanjay Dalal; Mark Kaplan; Michel Chonchol; Raymond M Hakim
Journal:  J Am Soc Nephrol       Date:  2013-12-26       Impact factor: 10.121

10.  National Kidney Foundation consensus conference on cardiovascular and kidney diseases and diabetes risk: an integrated therapeutic approach to reduce events.

Authors:  George Bakris; Joseph Vassalotti; Eberhard Ritz; Christoph Wanner; George Stergiou; Mark Molitch; Richard Nesto; George A Kaysen; James R Sowers
Journal:  Kidney Int       Date:  2010-08-18       Impact factor: 10.612

View more
  29 in total

Review 1.  Lipoproteins and fatty acids in chronic kidney disease: molecular and metabolic alterations.

Authors:  Heidi Noels; Michael Lehrke; Raymond Vanholder; Joachim Jankowski
Journal:  Nat Rev Nephrol       Date:  2021-05-10       Impact factor: 28.314

2.  Kidney function is associated with an altered protein composition of high-density lipoprotein.

Authors:  Katya B Rubinow; Clark M Henderson; Cassianne Robinson-Cohen; Jonathan Himmelfarb; Ian H de Boer; Tomas Vaisar; Bryan Kestenbaum; Andrew N Hoofnagle
Journal:  Kidney Int       Date:  2017-07-26       Impact factor: 10.612

3.  Increased apolipoprotein C3 drives cardiovascular risk in type 1 diabetes.

Authors:  Jenny E Kanter; Baohai Shao; Farah Kramer; Shelley Barnhart; Masami Shimizu-Albergine; Tomas Vaisar; Mark J Graham; Rosanne M Crooke; Clarence R Manuel; Rebecca A Haeusler; Daniel Mar; Karol Bomsztyk; John E Hokanson; Gregory L Kinney; Janet K Snell-Bergeon; Jay W Heinecke; Karin E Bornfeldt
Journal:  J Clin Invest       Date:  2019-07-11       Impact factor: 14.808

Review 4.  Unbiased and targeted mass spectrometry for the HDL proteome.

Authors:  Sasha A Singh; Masanori Aikawa
Journal:  Curr Opin Lipidol       Date:  2017-02       Impact factor: 4.776

5.  Lipids and Cardiovascular Risk with CKD.

Authors:  Farsad Afshinnia; Subramaniam Pennathur
Journal:  Clin J Am Soc Nephrol       Date:  2019-12-12       Impact factor: 8.237

Review 6.  Inflammation, remodeling, and other factors affecting HDL cholesterol efflux.

Authors:  Graziella E Ronsein; Tomáš Vaisar
Journal:  Curr Opin Lipidol       Date:  2017-02       Impact factor: 4.776

7.  Albuminuria, the High-Density Lipoprotein Proteome, and Coronary Artery Calcification in Type 1 Diabetes Mellitus.

Authors:  Baohai Shao; Leila R Zelnick; Jake Wimberger; Jonathan Himmelfarb; John Brunzell; W Sean Davidson; Janet K Snell-Bergeon; Karin E Bornfeldt; Ian H de Boer; Jay W Heinecke
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-05-16       Impact factor: 8.311

Review 8.  Quantifying HDL proteins by mass spectrometry: how many proteins are there and what are their functions?

Authors:  Baohai Shao; Jay W Heinecke
Journal:  Expert Rev Proteomics       Date:  2017-11-13       Impact factor: 3.940

Review 9.  Deepening our understanding of HDL proteome.

Authors:  Graziella Eliza Ronsein; Tomáš Vaisar
Journal:  Expert Rev Proteomics       Date:  2019-08-27       Impact factor: 3.940

10.  Alteration of HDL Protein Composition with Hemodialysis Initiation.

Authors:  Ke Wang; Leila R Zelnick; Andrew N Hoofnagle; Tomas Vaisar; Clark M Henderson; Peter B Imrey; Cassianne Robinson-Cohen; Ian H de Boer; Yan-Ting Shiu; Jonathan Himmelfarb; Gerald J Beck; Bryan Kestenbaum
Journal:  Clin J Am Soc Nephrol       Date:  2018-07-25       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.